Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-Blind Placebo-Controlled Multi-Center Proof-of-Concept Study to Assess the Efficacy of AIN457 in Patients With Psoriatic Arthritis

Next Previous
Search
Trial Profile

Randomized, Double-Blind Placebo-Controlled Multi-Center Proof-of-Concept Study to Assess the Efficacy of AIN457 in Patients With Psoriatic Arthritis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Secukinumab (Primary)
  • Indications Psoriatic arthritis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Novartis

    • Most Recent Events

    • 09 Nov 2011 Results for the parent study presented at the 75th Annual Scientific Meeting of the American College of Rheumatology and the 46th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 02 Feb 2011 New source identified and integrated (United Kingdom Clinical Research Network).
    • 07 Apr 2009 Actual initiation date (Mar 2009) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top